---
title: Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects
nct_id: NCT06126718
overall_status: COMPLETED
phase: PHASE1
sponsor: BioRay Pharmaceutical Co., Ltd.
study_type: INTERVENTIONAL
primary_condition: Psoriasis
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06126718.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06126718"
ct_last_update_post_date: 2025-06-24
last_seen_at: "2026-05-12T06:05:24.583Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects

**NCT ID:** [NCT06126718](https://clinicaltrials.gov/study/NCT06126718)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 88
- **Lead Sponsor:** BioRay Pharmaceutical Co., Ltd.
- **Conditions:** Psoriasis
- **Start Date:** 2024-02-21
- **Completion Date:** 2024-08-19
- **CT.gov Last Update:** 2025-06-24

## Brief Summary

This is a randomized, open-label, controlled Phase I study of BR201 administered by subcutaneous injection. This study will characterize the pharmacokinetic, safety and immunogenicity of BR201 versus Cosentyx（Secukinumab ） in healthy male subjects after a single dose.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 50 Years
- **Sex:** MALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Able to understand and sign informed consent form；
* Healthy men 18-50 years of age at time of consent；
* Body weight of ≥50 kg and ≤ 80 kg and BMI ≥19 and ≤ 26 kg/m2.

Exclusion Criteria:

* Clinical laboratory examination results are abnormal and with clinical significance, or other clinical findings indicate diseases (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, tumor, pulmonary, immune, mental or cardiovascular and cerebrovascular diseases) with clinical significance;
* Use of IL-17 or other monoclonal antibodies in the last 6 months;
* Positive for anti-IL-17 antibodies at screening;
* Evidence of tuberculosis infection;
* With active infection at screening or have been hospitalized for a serious infection during the 8 months prior to screening or use of antibiotics within 2 weeks of enrollment;
* Anti-IL-17 antibody active ingredient, excipients or latex allergy;
* With severe bleeding factors that affect venous blood collection or unwilling to undergo venipuncture;
* Use drug treatment (including prescription drugs, over-the-counter drugs, health product etc.) within 14 days before screening;
* Surgery within 2 months prior to screening; or plan to have surgery during the study period;.
* Have received live vaccines within 6 months prior to screening, or have used any vaccines within 4 weeks prior to screening, or plan to be vaccinated during the trial.;
* History of malignant neoplasms；
* Hepatitis B and/or Hepatitis C; or HIV antigen/antibody positive; or Treponema pallidum antibody positive; .
* Blood donation or massive blood loss (\> 400 ml) within 3 months or blood loss (\> 200 ml) within 1 month before signing the informed consent; or plan to donate blood during the trial;
* Have a history of drug or substance abuse before screening; or positive drug abuse test results on the day of check-in;
* Acute disease occurred or with concomitant medication from the screening to use of the study drug.;
* Have pregnancy plan or sperm donation plan during the whole trial period and within 6 months after the completion of the study;
* Other conditions considered inappropriate to be included in this study.
```

## Arms

- **BR201** (EXPERIMENTAL)
- **Cosentyx (Secukinumab)** (ACTIVE_COMPARATOR)

## Interventions

- **BR201** (DRUG) — One-dosage on D1 and review pharmacokinetic and safety until D112 after drug given
- **Cosentyx（Secukinumab ）** (DRUG) — One-dosage on D1 and review pharmacokinetic and safety until D112 after drug given

## Primary Outcomes

- **AUC0-inf** _(time frame: Till Day112)_ — Area under the cure from 0 to infinite
- **Cmax** _(time frame: Till Day112)_ — The max concentration after drug given

## Secondary Outcomes

- **AUC0-t** _(time frame: Till Day112)_
- **Tmax** _(time frame: Till Day112)_
- **T1/2** _(time frame: Till Day112)_
- **Vz/F** _(time frame: Till Day112)_
- **CL/F** _(time frame: Till Day112)_
- **Immunogenicity** _(time frame: Till Day112)_
- **AE** _(time frame: Till Day112)_
- **Evaluation about injection site reactions** _(time frame: 0 mins, 0.5 hours, 24 hours and 72 hours after drug given)_
- **ECG** _(time frame: Till Day112)_
- **Incidence of laboratory abnormalities** _(time frame: Till Day112)_

## Locations (1)

- The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.the affiliated hospital of qingdao university|qingdao|shandong|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06126718.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06126718*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*